Content |
Nevro is an American developer of implantable spinal cord neurostimulators. The company offers a Senza device designed to control chronic pain in the torso and lower extremities. The device is approved for sale in Europe and the United States.
2022: Boston Scientific to pay Nevro another $85 million for patent infringement in spinal cord stimulation
In early August 2022, it became known that Boston Scientific would pay $85 million, in addition to the $20 million previously awarded by the court, to resolve a legal dispute over intellectual property issues with Nevro.
Nevro and Boston Scientific were embroiled in a decades-long dispute over spinal cord stimulation patents in which Nevro won numerous victories, including success in an appeals court in early 2022, but in doing so, Nevro was found to have violated Boston Scientific's intellectual property.
In accordance with the agreement, Nevro granted Boston Scientific a worldwide non-exclusive non-transferable license to conduct therapy without paresthesia at frequencies below 1.5 thousand. Hz. Nevro has previously distinguished its device on the basis that it provides pain relief without paresthesia.
In exchange, Boston Scientific will pay Nevro $85 million and provide a worldwide non-exclusive license without the right to transfer under the claimed patents. The two companies agreed not to sue each other over the current performance of their devices.
Shares of Nevro rose 4.3%, and analysts at J.P. Morgan see near-term benefits for the company, particularly cash injections and the likelihood of reduced legal costs. However, in the longer term, analysts see this agreement as a competitive loss.
The spinal cord stimulation technique is used to treat various kinds of pathological conditions accompanied by severe pain in the legs, in the back, in the perineum, spasticity in the lower extremities. It is also used to treat erectile dysfunction, impaired pelvic organ function. The technique consists in installing electrodes on the surface of the spinal cord, to which stimuli are supplied from a stimulator sewn under the skin.[1]
2016: Lawsuit against Boston Scientific
In late November 2016, Nevro sued medical device maker Boston Scientific, accusing the company of infringing several of its patents.
In a lawsuit sent to the U.S. District Court for the Northern District of California, Nevro said Boston Scientific illegally used proprietary technology that was originally used in a Nevro Senza product and brand-name treatment called HF10.
 | Nevro was founded in 2006 to create advanced technologies in the field of chronic pain management and improve the lives of patients, says President and CEO of Nevro Rami Elghandour. - Behind the intellectual property that underpins innovation in the medical sciences are long-term work, investment and risks that cannot be dispensed with to achieve meaningful market success. We are committed to continuing the development of medical innovation by protecting our intellectual property. |  |
Nevro is demanding a ban on illegal use of its technology, damages and legal costs. What compensation is in question is not specified.[2]
According to Wells Fargo Securities analysts, Nevro's lawsuit includes only one patent in which the company can expect to win in court. We are talking about a document registered with the American Patent Office, number 6,895,280. It describes a spinal cord stimulation system capable of changing the range of parameters and working with an implanted electrode. This patent expires in 2020.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |